introduction
Targeting the epidermal growth factor receptor (EGFR) is now an established therapeutic option in squamous cell head and neck cancer (SCHNC) in both the curative and palliative setting as shown in two recent landmark studies [1] [2] [3] . These studies are in line with the observed synergism between blockade of EGFR, cisplatin, and radiation against cancer cell survival in preclinical studies [4] [5] [6] [7] . The use of cetuximab with concurrent radiotherapy (RT) without a significant increase in mucosal toxicity is a distinct and unique advantage of this approach [1] . Hence, it is reasonable to infer that combining EGFR blockade with chemoradiotherapy (CTRT) can achieve the ideal state of improving locoregional control without enhancing the mucosal and hematological toxic effects that is often the hallmark of polychemotherapy with concurrent RT.
Gefitinib, an EGFR tyrosine kinase inhibitor (TKI), has been shown to be an active agent in recurrent/metastatic SCHNC with a response rate of 10.6% at a higher dose of 500 mg daily and 1.4% at the dose of 250 mg daily [8, 9] . No biomarker predictive of response to gefitinib has been found. We conducted a phase II study of gefitinib 500 mg daily in combination with cisplatin and concurrent RT in locally advanced SCHNC. The primary aim of this study was to analyze the impact of gefitinib on gene expression profiles that may lead to identification of predictive biomarkers of favorable outcome with the addition of gefitinib. The other aims included the evaluation of the feasibility and efficacy of this treatment schedule in Asian patients.
patients and methods eligibility criteria
In line with the primary aim of this study, only patients with accessible primary tumor sites for baseline and repeat biopsies after 2 weeks of gefitinib were selected. Other selection criteria included no prior treatment, good performance status of Eastern Cooperative Oncology Group zero to one, locally advanced stage III/IV disease, normal organ and bone marrow function, and absence of distant metastases. All patients gave written informed consent. The study was approved by the institutional review board.
patient evaluation
Two baseline tumor samples were taken before the first dose of gefitinib. One sample was placed in RNAlater immediately for the purpose of gene expression analysis and the second sample was placed in formalin for fixation and embedded in paraffin blocks. A repeat tumor sample was taken after 2 weeks of gefitinib, which is placed in RNAlater to study the impact of gefitinib on tumor gene expression. A repeat computed tomography (CT) or magnetic resonance (MR) imaging of the head and neck region was carried out after 3 weeks of gefitinib to evaluate the response. During CTRT and gefitinib, weekly toxicity assessments including hematology were carried out using the National Cancer Institute-Common Toxicity Criteria (version 3.0). The full renal and liver biochemistries were done before each cycle of cisplatin. A second repeat CT or MR imaging of the head and neck was done 8 weeks after completion of concurrent CTRT and gefitinib, thereafter every 6 months for the first 2 years, and then yearly from year 3 to 5. A chest X-ray was carried out yearly.
gefitinib treatment
Gefitinib 500 mg daily was started 3 weeks before the start of CTRT and would continue at the same dose into the CTRT phase and thereafter for 4 months as consolidation phase.
chemotherapy
Cisplatin was given at 20 mg/m2/day on days 1-4 during weeks 1, 4, and 7 of RT. This fractionated schedule was used due to the high incidence of breakthrough emesis despite 5-hydroxotryptamine 3 antagonist with highdose single-day cisplatin in our patients. This study was conducted before the availability of aprepitant in this center.
radiotherapy
The primary tumor and the entire neck were treated using a linear accelerator to provide 6 MV photons and electron beams of appropriate energies. The primary tumor and the clinically and radiologically involved nodes received 70 Gy in 7 weeks and the rest of the neck received 60 Gy in 6 weeks. The details of RT are provided in the supplemental Materials (available at Annals of Oncology online).
dose modifications
Only one dose reduction was permitted for gefitinib to 250 mg daily. Gefitinib would be reduced by one dose level in the event of grade 3 toxic effects or suspended in the event of grade 4 toxicity. It may be resumed at 500 mg/day during the consolidation phase with subsidence of the mucositis to grade 0-1. In the event of recurrence of grade 3 or 4 toxicity, gefitinib would be discontinued.
Cisplatin would proceed during the first, fourth, and seventh week of RT in the presence of adequate bone marrow, renal, and liver functions. In the event that the predetermined criteria of these organ functions were not met, the particular dose of cisplatin would be omitted, but RT would not be interrupted. In the event of grade 4 oropharyngeal mucositis, cisplatin would be omitted and RT may be interrupted for a week before resumption. 
RNA preparation and microarray analysis

EGFR FISH analysis
The details are provided in the supplemental Materials (available at Annals of Oncology online).
EGFR mutation analysis
statistical considerations
At the time this study was conceived, there was very little in the literature relating to the determination of sample sizes for gene expression studies. Lee and Whitmore [10] and others have discussed some of the theoretical issues involved. For the purpose of this study, the primary aim was essentially descriptive in nature. Thus, we based our sample size computations on the secondary aims instead. The end point of interest is 2-year disease-free survival (DFS). Using an estimate of 60% 2-year DFS, 30 patients would give us a 95% confidence interval (CI) of 49% to 83%.
The two-sample Student's t-test was applied to determine statistical significance of genes within the gene expression dataset. Subsequently, multiple testing correction was achieved using John Storey's false discovery rate (q value). The minimum criteria were set to q value = 0.05 for the selection of genes deemed significant for further analysis.
Further details including definitions of survival outcome definitions and methods of analysis are described in the supplemental Materials (available at Annals of Oncology online).
results
patient characteristics
Thirty-one patients were recruited from November 2004 to October 2007. Their characteristics were summarized in Table 1 . All patients except one had stage IV disease with the majority having T4 and/or N2 disease. None of the patients with oropharyngeal cancer were tested for human papilloma virus. The median age of smokers/exsmokers and nonsmokers was comparable and all seven females in the study were neversmokers.
toxic effects
The treatment schedule was generally well tolerated with the majority of the toxic effects confined to grade 0-2 severity (Table 2) . Grade 3-4 oropharyngitis that led to tube feeding happened in 26.6% of the patients, which compares favorably with our historical data of 39% when cisplatin/5-fluorouracil and concurrent RT was used [11] . Grade 3-4 myelosuppression was uncommon and confined to the CTRT phase. There was no neutropenic infection. However, one elderly patient died of Gefitinib at 500 mg daily was well tolerated with mainly grade 1-2 rashes and diarrhea. Of note is that gefitinib did not seem to contribute to RT-induced skin toxicity.
dose intensity
Twenty-nine (93.5%), 26 (83.9%), and 20 (64.5%) patients received the scheduled cisplatin for cycle 1, 2, and 3, respectively.
Fourteen patients (45%) completed all three cycles of cisplatin without dose delay, reduction, or deletion. The median overall relative dose intensity of cisplatin was 98% (interquartile range: 66.7%-100.0%). Seven patients (23%) completed the planned schedule of gefitinib medication. Ten patients had their dose reduced and 17 patients experienced dose interruptions, which range from 1 to 27 days. Seven patients (23%) completed the planned treatment schedule of cisplatin and gefitinib.
response to treatment
Three major responses were noted after 3 weeks of gefitinib alone [1 complete response (CR) and 2 partial response (PR)] with an overall response rate (ORR) of 9.7% (Table 3 ). The remaining had stable disease (SD) during the induction phase. One patient declined all treatment after <3 weeks of gefitinib and was not assessable for response. One patient had marked tumor necrosis with gefitinib treatment but measurements fell short of PR by RECIST criterion and are classified as SD (Figure 1 ). Twenty-five patients had major responses after the completion of CTRT giving a response rate of 80.6% (12 CR and 13 PR). Two patients died of noncancer-related causes during the CTRT phase (pneumonia and myocardial infarct, respectively) and hence not assessable for response subsequently.
survival outcome
The median follow-up time was 2.4 years (range: 0.2-5.5 years). Fourteen patients (45.2%) were still alive at time of analysis and their median follow-up time was 4.4 years (range: 2.6-5.5 years). Fourteen patients (45.2%) were alive and 13 (41.9%) were free of progressive disease (PD) at the time of analysis. Three patients were disease free but died of other causes. The median DFS time was 1.3 years and the 3-year DFS proportion was 42.9% (95% CI 25.0% to 59.6%). The median overall survival was 2.4 years and the 3-year overall survival proportion was 48.4% (95% CI 38.2% to 64.4%). Six patients died of other causes.
impact of smoking status and skin toxicity on response and survival outcome
The three major responses after gefitinib were seen in smokers/ exsmokers. No differences in CR or PR after completion of CTRT were noted between the never-smokers and ever-smokers. Smokers/exsmokers had a median DFS of 1.2 years and the median DFS for nonsmokers was not reached (but >2.6 years) at the time of analysis. DFS between smokers/exsmokers and nonsmokers was comparable (P = 0.2). The median overall survival for ever-smokers was 2.2 years and not reached (but >3.5 years) for the never-smokers at time of analysis. The 3-year survival rates for ever-smokers and never-smokers were 42.1% (95% CI 20.4% to 62.5%) and 58.3% (95% CI 27.0% to 80.1%), respectively. We correlated the degree of skin toxicity during the first 4 weeks of gefitinib treatment to response and survival outcome. Higher skin toxicity due to cumulative gefitinib use of longer than 4 weeks may lead to selection of patients who were responders to this agent and hence may result in the erroneous correlation of skin toxicity with favorable outcome. There was no difference in ORRs nor survival outcome between patients who had grade 0-1 and grade ‡2 skin toxicity to gefitinib. Table S2 , available at Annals of Oncology online). However, no discernible changes in expression of EGFR, MAPK, and AKT genes were observed after gefitinib (supplemental Figure S1 , available at Annals of Oncology online). Of interest is the significant downregulation of MMP11 with a 6.9-fold downregulation of its expression after 2 weeks of gefitinib in patients who eventually achieved complete radiological response. Patients who had significant upregulation of MMP11 expression had a median survival of 8.4 months (five patients) compared with 55.2 months for those who had downregulation or no change in MMP11 gene expressions (nine patients). Twenty-one patients (67.7%) had MMP11 protein expression analyzed and 57.1% were positive for cancer cell cytoplasmic expression. The presence of MMP11 expression did not predict for response (Table 4 ). However, there was significant association with overall survival (P = 0.02) and DFS (P = 0.009) with overexpression predicting for a significantly poorer outcome (Table 4) . Twenty-two (71.0%) and 23 patients (74.2%) had their EGFR protein expression and EGFR FISH analyzed, respectively. Only 15 patients had EGFR mutation status evaluated and among them 2 patients (both were ever-smokers) had a mutation (13.3%). The two mutations comprised a missense mutation at exon 18 (G719A) in a tongue primary and a deletion at exon 19 (del S752-I759) in a maxillary sinus primary. Both patients had SD after induction gefitinib and both died of PD at 16 and 12 months from diagnosis, respectively. Expression of EGFR and the EGFR FISH and mutation status did not correlate with response to gefitinib nor overall survival outcome (Table 4) . However, the small number of mutation-positive patients limits the power of interpretation. The molecular characteristics were compared between the ever-smokers and never-smokers and presented in Table 5 . No relationships were found between smoking status and the expression levels of MMP11, EGFR, EGFR FISH, and EGFR mutation.
Of interest is the observation of two never-smokers with tongue primary who were found to have a nucleotide position 2361 G>A transition in exon 20, which is identified as single nucleotide polymorphism Q787Q. One of these patients had marked tumor necrosis after induction gefitinib and went on to achieve radiological CR as stated above (Figure 1 ). The second patient achieved complete radiological and clinical response after completion of the treatment schedule and is currently alive and disease free for >5 years.
discussion
The story of EGFR tyrosine kinase inhibition in advanced nonsmall-cell lung cancer (NSCLC) with gefitinib or erlotinib is well known and is a good example of how identification of the right patient population to treat has firmly established its role in this disease [12] [13] [14] [15] [16] .
Gefitinib and erlotinib have been found to be active in SCHNC albeit at a modest level [8, 9, 17, 18] . Studies by Cohen et al. [8, 9] suggest that response to gefitinib may be dose dependent. The three-arm randomized study by Stewart et al. [18] that compared gefitinib 250 mg daily versus gefitinib 500 mg daily versus weekly i.v. methotrexate demonstrated no statistical difference in response rates nor survival outcome between the arms, although the response rate of gefitinib at 500 mg daily appeared to be slightly higher than the lower dose consistent with Cohen's studies (7.6% versus 2.7%). Predictive biomarker studies conducted were few and generally inconclusive [8, [18] [19] [20] [21] . Our study has shown the lack of correlation of EGFR protein expression and EGFR FISH with response and survival outcome.
This is consistent with the findings of the phase III study by Stewart et al. [18] , which is the largest study to date, that showed that EGFR FISH was not predictive of response or survival outcome to gefitinib. The presence of EGFR mutations is an established predictive biomarker in NSCLC and of the many types of known mutations, in-frame deletions of exon 19 and L858R substitution in exon 21 accounts for >90% of the drug-sensitive mutations [22] . However, several retrospective studies showed that EGFR mutations are distinctly less common in SCHNC. Lee et al. [23] from South Korea found three EGFR mutations (7.3%) in 41 SCHNC tumor samples. All the mutations were the same in-frame deletion mutation in exon 19 (E746_A750del) and occurred in current smokers with laryngeal carcinoma. A second Korean study showed EGFR mutations in 16% of 110 patients with squamous cell carcinoma of the tongue or tonsil [24] . Studies from Japan and the West showed low mutation rate ranging from 0% to 8% [25] [26] [27] . Cohen et al. [21] found no EGFR mutations in the eight EGFR TKI responders. Therefore, the evolving picture of EGFR mutation in SCHNC shows significant differences from the more established role of this mutation in NSCLC. First, these mutations are distinctly uncommon. It is uncertain whether these mutations are more common in Asian patients. However, the study by Na et al. [24] does suggest that they may be more frequent in tongue and tonsillar cancers. Second, the distribution of these mutations appears different from NSCLC in that mutations involving exon 20 were detected more frequently. A combined analysis of the mutation types from the literature as well as the current study showed that exon 20 mutations comprised 40% of all mutations (supplemental Table S3 , available at Annals of Oncology online). Finally, it is indeterminate whether SCHNC is addicted to these mutations. However, it is of interest that the two patients with tongue cancers who were good responders to gefitinib in our study carried the silent mutation Q787Q (Figure 1 ). This observation seems consistent with the findings in a Japanese study conducted in SCHNC cell lines [28] . They found this genotype in nine different cell lines, which showed a higher sensitivity (lower IC 50 value) to gefitinib than cell lines with the wild type EGFR. Stromelysin 3 or matrix metalloproteinase 11 (MMP11) was found to be a potential prognostic biomarker in this small sample of locally advanced SCHNC. Overexpression of this protein by IHC was shown to predict for poorer survival outcome and this was supported by gene expression data that showed that significant upregulation of MMP11 expression after gefitinib resulted in a poorer survival outcome. MMP11 is one of a family of at least 20 endopeptidases that are secreted by the tumor cells or stromal cells located adjacent to the invasive tumoral front or both [29] . The MMPs are believed to facilitate the invasive and metastatic behavior of cancer cells by altering the cell-matrix interactions and degradation of matrix proteins and studies have shown that these are expressed in oral cancer and may have roles in its progression [30] . The gene expression of MMP11 was shown to correlate with a more aggressive behavior in NSCLC and esophageal squamous cell carcinoma [31, 32] . Stromal and/or cancer cell overexpression of MMP11 by IHC predicted for poorer survival outcome in breast cancer [33, 34] . However, MMP11 protein expression was not shown to be prognostic in oral cancer, although when coexpressed with vascular endothelial growth factor, can predict for progression from precancerous stage to invasive cancer [35] . Our study showed that MMP11 is a potential prognostic biomarker in this largely stage IV locally advanced SCHNC supported by both gene expression and IHC analyses. Although the downregulation of MMP11 after gefitinib predicts for a better outcome in this cohort, it is unlikely that MMP11 is a specific target of gefitinib, as the expression did not correlates with response. Nevertheless, our present study and those of others [31, 32, 36] assumed that messenger RNA levels correlated well with protein activity and did not take into consideration the stability of MMP11, its rate of degradation and the presence of other posttranslational modifications of MMP11 such as methylation and phosphorylation, which are not well documented in the literature. Furthermore, the relative 'transcriptional activity' of MMP11 was also confirmed in the present study by immunohistochemical studies (Table 4) .
Combining gefitinib with cisplatin and RT is feasible and may be beneficial for an appropriately selected group of patients. This study, however, failed to uncover biomarker(s) that can predict for response to gefitinib even with careful incorporation of baseline and posttreatment tumor tissue collection in a prospective manner. There are several limiting factors to this approach. First, adequacy of tumor tissue for analysis is still a problem even in these selected patients with accessible primary sites for tumor samplings. Second, tumor heterogeneity may limit the power of analysis for changes in gene expression posttreatment. Finally, the sample size is inadequate for failing to take into account the low response rate expected of gefitinib and the dropout due to inadequate tumor cells during pre-and posttreatment biopsies, hence limiting the power of genomic analysis.
Despite the small sample size of this study, it appears that biomarkers predictive of response to gefitinib in SCHNC do not lie within the known anomalies affecting the EGFR gene or its products. Further studies should be encouraged to determine the predictive biomarker(s) in order to select the right patients for this useful agent. The role of MMP11 as a prognostic marker and the role it plays in carcinogenesis in SCHNC should also be explored further. 
